News and events
- All
- Events
- Press releases
- Publications
All
- All
- Events
- Press releases
- Publications
ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a ...
August 18, 2021
Read More
ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to ...
July 15, 2021
Read More
ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody ...
July 13, 2021
Read More
ExeVir Announces Close of $50 million/ EUR42 million Series A Financing
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising ...
March 16, 2021
Read More
ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, announces publication in BioRxiv of a paper by VIB scientists showing, ...
March 9, 2021
Read More